Eli Lilly yesterday posted a strong set of financials for the second quarter of 2013, and announced that they would be raising their forecast for the full-year. The Q2 results were aided by cost-cutting and strong sales of their blockbuster drug, Cymbalta. Net income soared by 36% to $1.25 billion, while turnover increased 6% to
Johnson & Johnson have reported strong results for their second quarter of 2013, with an 8.5% increase in sales. The increase was aided by robust results from their prostate cancer drug, Zytiga. Net income reached $3.83 billion, a major increase from the $1.41 billion from the previous year’s quarter 2 period, aided by the gain
AstraZeneca and Roche have initiated a new medicinal chemistry data-sharing consortium to accelerate drug discovery in a smarter way. The companies say they will share “a specific type of early research data related to drug design, which could further accelerate the discovery of high quality compounds with an increased chance of clinical success.” They will
Pharmaceutical giant AstraZeneca has announced it is setting up its new global headquarters, just south of Cambridge. The £330million research and development site will employ a skilled workforce of 2,000 people and will open by 2016. Research and Development will cease at Alderley Park in Cheshire and close its London headquarters. Many of these posts will
If the National Health Service improved just 8 areas of their activity then 212 of England’s Clinical Commissioning Groups (CCGs) would save more than £1.6 billion. Statistics were analysed in research by consultancy MedeAnalytics. This covers all patient-level activity and associated costs taking place in hospitals in England. From analysis, researchers have narrowed down 8
The major supermarket Tesco is forming an alliance with the charity Diabetes UK, to raise £10 million to create healthier communities to help those affected by or at risk of Diabetes. This alliance is recognising their shared views and opinions which have a common aim to help those affected by the disease. Diabetes UK is
Only Medics London office move to Bouverie Street On Friday May 24th, our London office will be moving from its current location in its offices in Quantum House, to 11-12 Bouverie Street. This move will more than double the office space from 700sq ft, to a new much bigger environment of 1,600sq ft – a
Icon continued their run of solid quarterly results, reporting an operating income of US $23.0 million, an increase of 96.0% year on year. Net revenues were also higher, at US $316.8 million. The income total included reorganisation, and other items amounting to US $4.41 million. Without these charges operating income was up to US $27.4
Elan Corp have confirmed that they have declined Royalty Pharma’s $11.25 per share acquisition bid, adding that the bid does not come near to what the drug maker is worth. Last week, Royalty decreased their bid from a previous offer which could have reached as high as $12, depending upon the pricing of a $1
Royalty Pharma have increased their bid to acquire Elan Corp, in a move that values the Irish drug maker to up to $7.30 billion. After being asked by the Irish Takeover Panel to make a tangible offer by May 10th or abandon their plans to buy Elan, Royalty has made what they describe as a
